Christy Samaras

873 total citations
57 papers, 437 citations indexed

About

Christy Samaras is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Christy Samaras has authored 57 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hematology, 38 papers in Molecular Biology and 26 papers in Oncology. Recurrent topics in Christy Samaras's work include Multiple Myeloma Research and Treatments (40 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (20 papers) and Protein Degradation and Inhibitors (16 papers). Christy Samaras is often cited by papers focused on Multiple Myeloma Research and Treatments (40 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (20 papers) and Protein Degradation and Inhibitors (16 papers). Christy Samaras collaborates with scholars based in United States, Canada and Switzerland. Christy Samaras's co-authors include Jason Valent, Faiz Anwer, Beth Faiman, Jack Khouri, Rajshekhar Chakraborty, Mazen Hanna, Joseph P. Donnelly, Asad Ikram, Brett W. Sperry and Frederic J. Reu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Christy Samaras

49 papers receiving 432 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christy Samaras United States 13 302 264 189 97 44 57 437
Michelle E. Maglio United States 8 188 0.6× 215 0.8× 149 0.8× 33 0.3× 4 0.1× 9 359
Danai Dima United States 12 170 0.6× 180 0.7× 233 1.2× 40 0.4× 19 0.4× 69 409
Alexandra Kouraklis‐Symeonidis Greece 12 103 0.3× 213 0.8× 50 0.3× 99 1.0× 20 0.5× 24 394
Maria Gavino United States 7 342 1.1× 484 1.8× 258 1.4× 152 1.6× 3 0.1× 10 591
Faiza Zafar United States 11 370 1.2× 447 1.7× 262 1.4× 60 0.6× 4 0.1× 40 507
Angelo Belotti Italy 14 245 0.8× 312 1.2× 201 1.1× 82 0.8× 3 0.1× 41 451
Stephen J. Harding United Kingdom 11 236 0.8× 230 0.9× 73 0.4× 75 0.8× 42 1.0× 18 405
Ioannis Panagiotidis Greece 10 255 0.8× 242 0.9× 155 0.8× 64 0.7× 48 1.1× 22 392
Amr Hanbali United States 9 108 0.4× 104 0.4× 74 0.4× 28 0.3× 7 0.2× 43 301
Samah Nassereddine United States 9 118 0.4× 199 0.8× 78 0.4× 66 0.7× 2 0.0× 20 375

Countries citing papers authored by Christy Samaras

Since Specialization
Citations

This map shows the geographic impact of Christy Samaras's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christy Samaras with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christy Samaras more than expected).

Fields of papers citing papers by Christy Samaras

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christy Samaras. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christy Samaras. The network helps show where Christy Samaras may publish in the future.

Co-authorship network of co-authors of Christy Samaras

This figure shows the co-authorship network connecting the top 25 collaborators of Christy Samaras. A scholar is included among the top collaborators of Christy Samaras based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christy Samaras. Christy Samaras is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dima, Danai, Fauzia Ullah, Beth Faiman, et al.. (2025). Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14‐Year Experience of an Academic Center. Hematological Oncology. 43(3). e70082–e70082.
2.
Samaras, Christy, Akriti Jain, Jason Valent, et al.. (2025). Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup?. Blood. 146(Supplement 1). 2248–2248.
3.
4.
Raza, Shahzad, Christy Samaras, Beth Faiman, et al.. (2024). Impact of T-Cell Redirecting Therapies on Survival Outcomes in Ultra-High-Risk Multiple Myeloma and Plasma Cell Leukemia. Blood. 144(Supplement 1). 7092–7092. 1 indexed citations
5.
Bahlis, Nizar J., Christy Samaras, Donna Reece, et al.. (2024). Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014. Clinical Lymphoma Myeloma & Leukemia. 24(12). 852–862. 2 indexed citations
6.
Bahlis, Nizar J., Christy Samaras, Donna Reece, et al.. (2023). MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S494–S495. 1 indexed citations
7.
Dima, Danai, Ang Li, Saeid Mirzai, et al.. (2023). External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. British Journal of Haematology. 201(2). 280–284. 7 indexed citations
8.
Xu, Xuan, Shahzad Raza, Jim E. Riviere, et al.. (2023). Identification of genes encoding targets associated with adverse events in multiple myeloma.. Journal of Clinical Oncology. 41(16_suppl). 1556–1556. 2 indexed citations
9.
10.
Raza, Shahzad, Xuan Xu, Beth Faiman, et al.. (2023). P-366 Signaling pathway data analytics of nephropathy and neuropathy from drug toxicities in multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S241–S241. 1 indexed citations
11.
Bahlis, Nizar J., Gary J. Schiller, Christy Samaras, et al.. (2022). P-232: Adverse event patterns and management with pomalidomide, dexamethasone, and daratumumab in patients with relapsed or refractory multiple myeloma: a safety analysis of the phase 2 MM-014 study. Clinical Lymphoma Myeloma & Leukemia. 22. S162–S163. 1 indexed citations
12.
Covut, Fahrettin, Sanchit Chawla, Christy Samaras, et al.. (2021). Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. British Journal of Haematology. 193(6). 1213–1219. 25 indexed citations
13.
Randhawa, Varinder K., Sneha Vakamudi, Dermot Phelan, et al.. (2020). Mitral and Tricuspid Stenosis Caused by Light Chain Cardiac Amyloid Deposition. ESC Heart Failure. 7(3). 1130–1135. 8 indexed citations
14.
Chaulagain, Chakra P., Leah Elson, Raymond L. Comenzo, et al.. (2020). Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients. Clinical Lymphoma Myeloma & Leukemia. 20(3). e137–e143. 7 indexed citations
15.
Anwer, Faiz, Ahmad Iftikhar, Mirza Muhammad Faran Ashraf Baig, et al.. (2019). Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(7). 397–405. 13 indexed citations
16.
Khouri, Jack, Christy Samaras, Jason Valent, et al.. (2019). Monoclonal gammopathy of undetermined significance: A primary care guide. Cleveland Clinic Journal of Medicine. 86(1). 39–46. 5 indexed citations
17.
Durer, Ceren, Seren Durer, Sarah Lee, et al.. (2019). Treatment of relapsed multiple myeloma: Evidence-based recommendations. Blood Reviews. 39. 100616–100616. 42 indexed citations
18.
Ikram, Asad, Joseph P. Donnelly, Brett W. Sperry, et al.. (2018). Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center’s experience. Amyloid. 25(3). 197–202. 50 indexed citations
19.
20.
Sidana, Surbhi, Mayur Narkhede, Paul Elson, et al.. (2017). Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS ONE. 12(3). e0172996–e0172996. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michelle E. Maglio Breakdown of academic impact, for papers by Danai Dima Breakdown of academic impact, for papers by Alexandra Kouraklis‐Symeonidis Breakdown of academic impact, for papers by Maria Gavino Breakdown of academic impact, for papers by Faiza Zafar Breakdown of academic impact, for papers by Angelo Belotti Breakdown of academic impact, for papers by Stephen J. Harding Breakdown of academic impact, for papers by Ioannis Panagiotidis Breakdown of academic impact, for papers by Amr Hanbali Breakdown of academic impact, for papers by Samah Nassereddine
Rankless by CCL
2026